Racial differences in eligibility and enrollment in a smoking cessation clinical trial

Andrea C King, Dingcai Cao, Catherine C Southard, Alicia Matthews, Andrea C King, Dingcai Cao, Catherine C Southard, Alicia Matthews

Abstract

Objective: The purpose of this study was to compare the recruitment, eligibility screening, and enrollment of African American and White smokers into an intensive smoking cessation intervention trial [The Chicago STOP Smoking Trial (C-STOP)].

Methods: We compared demographic, smoking, substance use, and medical/psychiatric screening data from the recruitment records of 1,189 non-Hispanic, African American and White smokers screened for eligibility in the last year of a randomized pharmacological and behavioral smoking cessation trial. The study took place at a large urban medical center and two satellite locations within the Chicago metropolitan area.

Results: Interest levels in the study were high among African American smokers, with twice as many African Americans as Whites contacting study staff for information and an initial screening. However, African Americans were nearly three times as likely not to be enrolled in the trial as Whites, because of higher ineligibility rates, failure to attend a screening session, and lower participation rates even among those meeting eligibility requirements.

Conclusions: Racial differences were observed nearly at all levels of enrollment determination. These critical barriers to inclusion of African Americans in smoking cessation research limit our understanding of treatment efficacy and ultimately the ability to reduce the health disparities in tobacco-related disease experienced by African Americans.

(PsycINFO Database Record (c) 2010 APA, all rights reserved).

Figures

Figure 1
Figure 1
CONSORT diagram of eligibility determination in 1,189 non-Hispanic African American and White Smokers. Stages include telephone screening eligibility, attending the in-person screening, in-person screening eligibility, and electing to enroll in the trial among those deemed eligible. 1due to rounding, % totals may not equal 100% in all cases

References

    1. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for smoking cessation in African Americans. Journal of the American Medical Association. 2002;288(4):468–474.
    1. Ahluwalia JS, McNagny SE, Clark WS. Smoking cessation among inner-city African Americans using the nicotine transdermal patch. Journal of General Internal Medicine. 1998;13(1):1–8.
    1. Audrain-McGovern J, Halbert C, Rodriguez D, Epstein LH, Tercyak KP. Predictors of participation in a smoking cessation program among young adult smokers. Cancer Epidemiology, Biomarkers, & Prevention. 2007;16(3):617.
    1. Barbeau EM, Krieger N, Soobader MJ. Working class matters: socioeconomic disadvantage, race/ethnicity, gender and smoking in NHIS 2000. American Journal of Public Health. 2004;94(2):269–278.
    1. Benowitz NL. Smoking cessation trials targeted to racial and economic minority groups. Journal of General Internal Medicine. 2002;288(4):497–499.
    1. Brodie M, Flournoy RE, Altman DE, Blendon RJ, Benson JM, Rosenbaum MD. Health information, the Internet, and the digital divide. Health Affairs. 2000;19(6):255–265.
    1. Centers for Disease Control and Prevention. State-Specific Prevalence of Current Cigarette Smoking Among Adults – Unites States, 2002. Morbidity and Mortality Weekly Review. 2004;52(53):1277–1280.
    1. Centers for Disease Control and Prevention. Annual smoking: attributable mortality, years of potential life lost, and productivity losses – United States, 1997-2001. Morbidity and Mortality Weekly Review. 2005;54(25):625–628.
    1. Centers for Disease Control and Prevention. Cigarette smoking among adults - United States, 2006. Morbidity and Mortality Weekly Review. 2007;56(44):1157–1161.
    1. Center for Disease Control and Prevention. Summary Health Statistics for US Adults: National Health Interview Survey, 2008. U.S. Department of Health and Human Services, Publication No. (PHS) 2010-1570; 2009. Vital and Health Statistics, Series 10, Number 242.
    1. Clark PI, Gautham S, Gerson LW. Effect of menthol cigarettes on biochemical markers of smoke sxposure among black and whit smokers. Chest. 1996;110(5):1194–1198.
    1. Covey LS, Glassman AH, Stetner F. Naltrexone effects on short-term and long-term smoking cessation. Journal of Addictive Diseases. 1999;18(2):31–40.
    1. Dahm JL, Cook E, Baugh K, Wileyto EP, Pinto A, Leone F, et al. Schnoll RA. Predictors of enrollment in a smoking cessation clinical trial after eligibility screening. Journal of the National Medical Association. 2009;101(5):451–455.
    1. Dickerson DL, Leeman RF, Mazure CM, O’Malley SS. The inclusion of women and minorities in smoking cessation clinical trials: a systematic review. American Journal on Addictions. 2009;18(1):21–28.
    1. Fagan P, King G, Lawrence D, Patrucci SA, Robinson RG, Banks D, et al. Grana R. Eliminating tobacco-related health disparities: directions for future research. American Journal of Public Health. 2004;94(2):211–217.
    1. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Wewers ME. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008. Treating Tobacco Use and Dependence: 2008 Update.
    1. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I/NP) New York: Biometrics Research, New York State Psychiatric Institute; 1995.
    1. Fitzgibbon ML, Prewitt TE, Blackman LR, Simon P, Luke A, Keys LC, et al. Singh V. Quantitative assessment of recruitment efforts for prevention trials in two diverse black populations. Preventive Medicine. 1998;27(6):838–845.
    1. Fu SS, Kodl MM, Joseph AM, Hatsukami DK, Johnson EO, Breslau N, et al. Bierut L. Racial/Ethnic disparities in the use of nicotine replacement therapy and quit ratios in lifetime smokers ages 25 to 44 years. Cancer Epidemiology, Biomarkers, & Prevention. 2008;17(7):1640–1647.
    1. Gariti P, Levin S, Whittingham T, Barou D, Kampman KM, Lynch K, et al. Alterman A. Why do those who request smoking treatment fail to attend the first appointment? Journal of Substance Abuse Treatment. 2008;35(1):2–67.
    1. Garrow JS, Webster J. Quetelet’s index (W/H2) as a measure of fatness. International Journal of Obesity. 1985;9(2):147–153.
    1. Gandhi KK, Foulds J, Steinberg MB, Lu SE, Williams JM. Lower quit rates among African American and Latino menthol cigarette smokers at a tobacco treatment clinic. International Journal of Clinical Practice. 2009;63(3):360–367.
    1. Giovino GA, Sidney S, Gfroerer JC, O’Malley PM, Allen JA, Richter PA. Epidemiology of menthol cigarette use. Nicotine & Tobacco Research. 2004;6:S67–S81.
    1. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Reeves KR. Varenicline, an αaβ2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation. Journal of General Internal Medicine. 2006;296(1):47–55.
    1. Harris KJ, Ahluwalia JS, Catley D, Okuyemi KS, Mayo MS, Resnicow K. Successful recruitment of minorities into clinical trials: the Kick It at Swope project. Nicotine & Tobacco Research. 2003;5(4):575–584.
    1. Heatherton TF, Kozlowshi LT, Frecker RC, Fagerström K. The Fagerström Test for Nicotine Dependence: A revision of the Fagerstrom tolerance questionnaire. British Journal of Addiction. 1991;86(9):1119–1127.
    1. Hjalmarson AI, Franzon M, Westin A, Wiklund O. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. Archives of Internal Medicine. 1994;154(22):2567–2572.
    1. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al.Edwards BK, editors. National Cancer Institute; Bethesda, MD: 2009. SEER Cancer Statistics Review, 1975-2006. , based on November 2008 SEER data submission, posted to the SEER web site.
    1. Hurt RD, Sachs DP, Gliver ED, Offorf KP, Johnston JA, Dale LC, et al. Sullivan PM. A comparison of sustained-release bupropion and placebo for smoking cessation. New England Journal of Medicine. 1997;337(17):1195–1202.
    1. Jeffries SK, Choi W, Butler J, Harris KJ, Ahluwalia JS. Strategies for recruiting African-American residents of public housing developments into a randomized controlled trial. Ethnicity & Disease. 2005;15(4):773–778.
    1. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Reeves KR. Efficacy of varenicline, an αaβ2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Journal of General Internal Medicine. 2006;296(1):56–63.
    1. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. Baker TB. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine. 1999;340(9):685–691.
    1. Kaiser Family Foundation . Data Source: Centers for Disease Control and Prevention. HIV Surveillance Supplemental Report, Midyear Edition. Characteristics of Persons Living with AIDS at the End of 1999 2001;12(1)
    1. Kiefe CI, Williams OD, Lewis CE, Allison JJ, Sekar P, Wagenknecht LE. Ten-year changes in smoking among young adults: are racial differences explained by socioeconomic factors in the CARDIA study? American Journal of Public Health. 2001;91(2):213–218.
    1. King AC, Cao D. Naltrexone effects on smoking cessation quit rates, urges, and weight gain: an examination of sex differences. Paper presentation at the annual conference of the Society for Research on Nicotine and Tobacco; Baltimore, MD. 2010.
    1. King AC, Cao D, Southard C, Matthews A. Racial disparities in screening and eligibility determination in a smoking cessation clinical trial. Paper presented at the annual conference of the Society for Research on Nicotine and Tobacco; Baltimore, MD. 2010.
    1. King AC, de Wit H, Riley RC, Cao D, Niaura R, Hatsukami D. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine & Tobacco Research. 2006;8(5):671–682.
    1. King AC, Sánchez-Johnsen L, Van Orman S, Cao D, Matthews AK. A pilot community-based intensive smoking cessation intervention in African Americans: feasibility, acceptability, and early outcome indicators. Journal of the National Medical Association. 2008;100(2):208–217.
    1. King G, Polednak A, Bendel RB, Vilsaint MC, Nahata SB. Disparities in smoking cessation between African Americans and Whites: 1990-2000. American Journal of Public Health. 2004;94(11):1965–1971.
    1. Kreuter MW, Lukwago SN, Bucholtz RD, Clark EM, Sanders-Thompson V. Achieving cultural appropriateness in health promotion programs: targeted and tailored approaches. Health Education & Behavior. 2003;30(2):133–146.
    1. Lacey LP, Manfredi C, Balch G, Warnecke RB, Allen K, Edwards C. Social support in smoking cessation among black women in Chicago public housing. Public Health Reports. 1993;108(3):387–394.
    1. Lee RE, McGinnis KA, Sallis JF, Castro CM, Chen AH, Hickmann SA. Active vs. passive methods of recruiting ethnic minority women to a health promotion program. Annals of Behavioral Medicine. 1997;19(4):378–384.
    1. Lorence DP, Park H, Fox S. Racial disparities in health information access: resilience of the digital divide. Journal of Medical Systems. 2006;30(4):241–249.
    1. Matthews AK, Sánchez-Johnsen L, King AC. Development of a culturally targeted smoking cessation intervention for African American smokers. Journal of Community Health. 2009;34(6):480–492.
    1. Mazas CA, Wetter DW. Smoking cessation interventions among African Americans: research needs. Cancer Control. 2003;10(5 suppl):87–89.
    1. Nollen NS, Mayo MS, Sanderson Cox L, Okuyemi KS, Kaur H, Ahluwalia JS. Predictors of quitting among African American light smokers enrolled in a randomized, placebo-controlled trial. Journal of General Internal Medicine. 2006;21(6):590–595.
    1. O’Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, et al. Jatlow P. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Archives of Internal Medicine. 2006;166(6):667–674.
    1. Piper ME, Fox BJ, Welsch SK, Fiore MC, Baker TB. Gender and racial/ethnic differences in tobacco-dependence treatment: a commentary and research recommendations. Nicotine & Tobacco Research. 2001;3(4):291–7.
    1. Pérez-Stable EJ, Herrera B, Jacob P, 3rd, Benowitz NL. Nicotine metabolism and intake in black and white smokers. Journal of General Internal Medicine. 1998;280(2):152–156.
    1. Robles GI, Singh-Franco D, Ghin HL. A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations. Clinical Therapeutics. 2008;30(5):800–812.
    1. Royce JM, Hymowitz N, Corbett K, Hartwell TD, Orlandi MA. Smoking cessation factors among African Americans and Whites. American Journal of Public Health. 1993;83(2):220–226.
    1. Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo controlled trial. Addiction. 1996;91(9):1293–1306.
    1. Shaya FT, Gbaravor CM, Huiwen KY, Agyeman-Dauh M, Saunders E. A perspective on African American participation in clinical trials. Contemporary Clinical Trials. 2007;28(2):213–217.
    1. Shiffman S. Light and intermittent smokers: background and perspective. Nicotine & Tobacco Research. 2009;11(2):122–125.
    1. Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. Archives of Internal Medicine. 2002a;162(11):1267–1276.
    1. Shiffman S, Rolf CN, Hellebusch SJ, Gorsline J, Gorodetzky CW, Chiang YK, et al. Di Marino ME. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction. 2002b;97(5):505–516.
    1. Signorello LB, Cai Q, Tarone RE, McLaughlin JK, Blot WJ. Racial differences in serum cotinine levels of smokers. Disease Markers. 2009;27(5):187–92.
    1. Staffileno BA, Coke LA. Recruiting and retaining young, sedentary, hypertension-prone African American women in a physical activity intervention study. Journal of Cardiovascular Nursing. 2006;21(3):208–216.
    1. Targonski PV, Persky VW, Orris P, Addington W. American Journal of Public Health. Vol. 84. Illinois Department of Health. Tobacco Burden in Illinois; 2005. [October 2, 2006]. Trends in asthma mortality among African Americans and Whites in Chicago, 1968 through 1991; pp. 1830–1833. Available at: .
    1. Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. Journal of General Internal Medicine. 1993;269(10):1268–71.
    1. Tonstad S, Tonnesen P, Hajk P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. Journal of General Internal Medicine. 2006;296(1):64–71.
    1. U.S. Census Bureau. Chicago Community Area (CCA) Profiles. Census Data for the City of Chicago 2000
    2. Wagenknecht LE, Cutter GR, Haley NJ, Sidney S, Manolio TA, Hughes GH, Jacobs DR. Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study. American Journal of Public Health. 1990;80(9):1053–6.
    1. Webb MS, Seigers D, Wood EA. Recruiting African American smokers into intervention research: relationships between recruitment strategies and participant characteristics. Research in Nursing & Health. 2009;32(1):86–95.
    1. Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD. A randomized trial of naltrexone for smoking cessation. Addiction. 1999;94(8):1227–1237.
    1. Woods MN, Harris KJ, Mayo MS, Catley D, Scheibmeir M, Ahluwalia JS. Participation of African Americans in a smoking cessation trial: a quantitative and qualitative study. Journal of the National Medical Association. 2002;94(7):609–618.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren